NERATINIB (HKI-272), AN IRREVERSIBLE PAN ERBB RECEPTOR TYROSINE KINASE INHIBITOR: PHASE 2 RESULTS IN PATIENTS WITH ERBB2+ADVANCED BREAST CANCER

被引：0
|
作者：
Paridaens, R. [1 ]
Badwe, R. [2 ]
Sun, Y. [3 ]
Dirix, L. [4 ]
Cardoso, F. [5 ]
Powell, C. [6 ]
Zacharchuk, C. [7 ]
Burstein, H. J. [8 ]
机构：
[1] Univ Hosp Gasthuisberg Katholieke, Leuven, Belgium
[2] Tata Mem Hosp, Dept Surg Oncol, Mumbai 400012, Maharashtra, India
[3] Chinese Acad Med Sci, Beijing 100037, Peoples R China
[4] AZ St Augustinus, Oncol, Antwerp, Belgium
[5] Inst Jules Bordet, Med Oncol & Translat Res Unit, B-1000 Brussels, Belgium
[6] Wyeth Ayerst Res, Biostat, Cambridge, MA USA
[7] Wyeth Ayerst Res, Oncol, Cambridge, MA USA
[8] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：61 / 61
页数：1
相关论文
共 50 条
  • [31] Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions
    Ocana, Alberto
    Amir, Eitan
    CANCER TREATMENT REVIEWS, 2009, 35 (08) : 685 - 691
  • [32] Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells
    Canfield, Kaleigh
    Li, Jiaqi
    Wilkins, Owen M.
    Morrison, Meghan M.
    Ung, Matthew
    Wells, Wendy
    Williams, Charlotte R.
    Liby, Karen T.
    Vullhorst, Detlef
    Buonanno, Andres
    Hu, Huizhong
    Schiff, Rachel
    Cook, Rebecca S.
    Kurokawa, Manabu
    CELL CYCLE, 2015, 14 (04) : 648 - 655
  • [33] Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor
    Rao, GS
    Murray, S
    Ethier, SP
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (05): : 1519 - 1528
  • [34] Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor
    Fry, DW
    Bridges, AJ
    Denny, WA
    Doherty, A
    Greis, KD
    Hicks, JL
    Hook, KE
    Keller, PR
    Leopold, WR
    Loo, JA
    McNamara, DJ
    Nelson, JM
    Sherwood, V
    Smaill, JB
    Trumpp-Kallmeyer, S
    Dobrusin, EM
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (20) : 12022 - 12027
  • [35] NERATINIB MONOTHERAPY IN PATIENTS WITH ADVANCED ERBB2-POSITIVE BREAST CANCER: GASTROINTESTINAL AND CARDIOVASCULAR SAFETY PROFILES
    Dirix, L. Y.
    Badwe, R.
    Sun, Y.
    Paridaens, R.
    Lebrun, F.
    Powell, C.
    Turnbull, K.
    Zacharchuk, C.
    Burstein, H. J.
    ANNALS OF ONCOLOGY, 2010, 21 : 61 - 62
  • [36] Gastrointestinal and Cardiovascular Safety Profiles of Neratinib Monotherapy in Patients with Advanced ErbB2-Positive Breast Cancer
    Burstein, H. J.
    Sun, Y.
    Dirix, L.
    Jiang, Z.
    Paridaens, R.
    Tan, A. R.
    Awada, A.
    Ranade, A.
    Jiao, S.
    Schwartz, G.
    Powell, C.
    Turnbull, K.
    Vermette, J.
    Zacharchuk, C.
    Badwe, R.
    CANCER RESEARCH, 2009, 69 (24) : 797S - 798S
  • [37] Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer
    Martinello, Rossella
    Milani, Andrea
    Geuna, Elena
    Zucchini, Giorgia
    Aversa, Caterina
    Nuzzo, Annamaria
    Montemurro, Filippo
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (04) : 393 - 403
  • [38] Cl-1033, an irreversible pan-erbB receptor inhibitor and its potential atmlication for the treatment of breast cancer
    Allen, LF
    Eiseman, IA
    Fry, DW
    Lenehan, PF
    SEMINARS IN ONCOLOGY, 2003, 30 (05) : 65 - 78
  • [39] Neratinib, an irreversible pan-ErbB receptor inhibitor, is highly effective against primary cervical cancer cell lines harboring HER2/neu gene mutations
    Lopez, S.
    Bellone, S.
    Black, J. D.
    Schwab, C. L.
    English, D. P.
    Terranova, C.
    Schwartz, P. E.
    Rutherford, T. J.
    Angioli, R.
    Santin, A.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 144 - 144
  • [40] The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells
    Booth, Laurence
    Roberts, Jane L.
    Avogadri-Connors, Francesca
    Cutler, Richard E., Jr.
    Lalani, Alshad S.
    Poklepovic, Andrew
    Dent, Paul
    CANCER BIOLOGY & THERAPY, 2018, 19 (03) : 239 - 247
12345